COVID 19 Spike RBD Neutralizing Coronavirus (COVID-19) Antibody – Human Monoclonal

Human monoclonal anti-spike RBD (SARS-CoV-2/COVID-19) neutralizing antibody produced by invitro XtenCHO cells

Introduction: The novel corona virus (SARS-CoV-2), previously called 2019-nCoV, is a newly identifiedcorona virus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019.
The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82%with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope,Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS corona viruses. However, the external subdomain of Spike's receptor binding domain (RCB) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related corona viruses.

Small volumes of anti-COVID-19 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS430580 is an antibody targeting COVID-19. Also known as Anti-Spike RBD (SARS-CoV-2/COVID-19) Human Neutralizing Antibody. Host: Human.